VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. "Each year, EASD provides a high-profile opportunity to highlight our latest product innovations and new clinical data that demonstrates how Dexc. ...

MELBOURNE, Australia (AP) — One of Australia’s largest banks said Monday it agreed to pay a record 240 million Australian dollars ($160 million) in penalties for corporate misconduct affecting almost 65,000 customers and the federal government. Melbourne-based ANZ, also known as Australia and New Zealand Banking Group, and the Australian Securities and Investments Commission said in statements they will ask a federal court to endorse the penalties for four separate prosecutions. The fines would set a new ...

Market Analysis by covering: S&P 500, Oracle Corporation, United States 10-Year, CBOE Volatility Index. Read 's Market Analysis on Investing.com ...

Group 1 - TotalEnergies and QatarEnergy executives met with Iraqi officials to discuss energy collaboration [1] - The meeting included discussions with Iraq's Prime Minister and Minister of Oil [1]

Duquesne Family Office's billionaire boss bid adieu to a "magnificent" stock and absolutely gobbled up shares of what had been a remarkably cheap media company.For a lot of investors, earnings season is the pinnacle of each quarter. The six-week period where a majority of S&P 500 businesses report their operating results gives investors invaluable information on the health of the U.S. economy.But earnings season isn't the only important data dump of the quarter. Aug. 14 marked the deadline for institutional ...

Core Viewpoint - First Hydrogen Corp. supports Canada's fast-tracking of the Darlington Small Modular Reactor (SMR) project, aligning with its green energy strategy and aiming to be a leader in SMR technology [1][3]. Group 1: Company Developments - First Hydrogen Corp. is collaborating with the University of Alberta to optimize SMR design and fuel materials, addressing the growing energy demands of AI data centers, which are projected to increase global power demand by 50% by 2027 and 165% by 2030 [2]. - The company launched First Nuclear Corp. in March 2025 to integrate SMR power with electrolysis for green hydrogen production, targeting off-grid and industrial sites [3]. - First Hydrogen has developed two hydrogen fuel-cell-powered light commercial vehicles (FCEV) that have completed 6,000 km of testing and achieved a range of over 630 kilometers on a single refueling [5]. Group 2: Industry Context - The Darlington SMR project is positioned as a national priority for Canada, aiming to make it the first G7 country with an operational SMR, which supports the country's energy infrastructure and climate goals [1][4]. - SMRs are designed to be factory-built and suitable for small-scale applications, providing energy for approximately 300,000 homes [1]. - The anticipated US$720 billion in grid spending through 2030 highlights the significant investment needed to support the growing energy demands, particularly from data centers [2].

Core Insights - BioNxt Solutions Inc. has successfully completed proof-of-concept trials for its Semaglutide oral dissolvable film program at its wholly owned subsidiary, Vektor Pharma TF GmbH [1] Group 1 - The trials involved the evaluation of multiple proprietary film platforms at Vektor Pharma [1]

Group 1 - The company Plains All American Pipeline (NASDAQ: PAA) has missed earnings expectations for two consecutive quarters, which may impact investor sentiment and future performance [1] - The analyst has previously outlined a detailed investment thesis for Plains All American Pipeline, indicating a belief in its potential as a buy opportunity [1] Group 2 - The analyst possesses a diverse professional background across multiple industries, including logistics, construction, and retail, which contributes to a comprehensive investment perspective [1] - The investment strategy focuses on cyclical industries, aiming for significant returns during economic recovery while maintaining a diversified portfolio that includes bonds, commodities, and forex [1]

Core Viewpoint - The company, founded by industry titan Martin Sorrell, has lowered its like-for-like net revenue projection for the second time in three months, citing volatility partly triggered by U.S. tariffs [1] Group 1 - The company has experienced significant volatility in its operations [1] - The reduction in revenue projections indicates challenges in the current market environment [1] - U.S. tariffs are identified as a contributing factor to the company's financial adjustments [1]

Company Highlights - Aurinia Pharmaceuticals Inc. (AUPH) has seen solid growth for its product LUPKYNIS, with expected net product sales for 2025 ranging from $250 million to $260 million, up from $216.2 million last year [2][3] - Arrowhead Pharmaceuticals Inc. (ARWR) is preparing for its first commercial launch in 2025, with its lead drug candidate Plozasiran under FDA review, decision expected on November 18, 2025 [4][5] - Beta Bionics Inc. (BBNX) reported a 54% growth in second-quarter net sales, with expectations for full-year 2025 net sales to range between $88 million and $93 million, compared to $65.1 million last year [7][8] - Kiniksa Pharmaceuticals International plc (KNSA) anticipates net product revenue for its drug Arcalyst to be between $625 million and $640 million for 2025, up from $417 million in 2024 [10][11] - Ionis Pharmaceuticals Inc. (IONS) generated net product sales of $19 million in Q2 2025, with a supplemental new drug application expected by year-end [12][14] - Stoke Therapeutics Inc. (STOK) is developing Zorevunersen for Dravet syndrome, with a 52-week high of $24.60 reached recently, representing an 82% gain in less than two months [16][17] - Fortress Biotech Inc. (FBIO) is awaiting an FDA decision on its investigational drug CUTX-101 for Menkes disease, expected on September 30, 2025 [18][21] Stock Performance - AUPH stock increased by 168% over 1.5 years, reaching a 52-week high of $12.87 [3] - ARWR stock gained 65% in less than 9 months, hitting a 52-week high of $31.13 [5] - BBNX stock rose nearly 55% in less than 4 months, reaching a 52-week high of $26.66 [8] - KNSA stock saw a 46% increase in less than four months, touching a 52-week high of $37.34 [11] - IONS stock gained 52% in less than two months, reaching a 52-week high of $64.72 [15] - STOK stock increased by 82% in less than two months, achieving a 52-week high of $24.60 [17] - FBIO stock rose by 61% in less than a month, reaching a 52-week high of $3.97 [21]